RESUMEN
BACKGROUND: In March 2014, the World Health Organization was notified of an outbreak of Zaire ebolavirus in a remote area of Guinea. The outbreak then spread to the capital, Conakry, and to neighboring countries and has subsequently become the largest epidemic of Ebola virus disease (EVD) to date. METHODS: From March 25 to April 26, 2014, we performed a study of all patients with laboratory-confirmed EVD in Conakry. Mortality was the primary outcome. Secondary outcomes included patient characteristics, complications, treatments, and comparisons between survivors and nonsurvivors. RESULTS: Of 80 patients who presented with symptoms, 37 had laboratory-confirmed EVD. Among confirmed cases, the median age was 38 years (interquartile range, 28 to 46), 24 patients (65%) were men, and 14 (38%) were health care workers; among the health care workers, nosocomial transmission was implicated in 12 patients (32%). Patients with confirmed EVD presented to the hospital a median of 5 days (interquartile range, 3 to 7) after the onset of symptoms, most commonly with fever (in 84% of the patients; mean temperature, 38.6°C), fatigue (in 65%), diarrhea (in 62%), and tachycardia (mean heart rate, >93 beats per minute). Of these patients, 28 (76%) were treated with intravenous fluids and 37 (100%) with antibiotics. Sixteen patients (43%) died, with a median time from symptom onset to death of 8 days (interquartile range, 7 to 11). Patients who were 40 years of age or older, as compared with those under the age of 40 years, had a relative risk of death of 3.49 (95% confidence interval, 1.42 to 8.59; P=0.007). CONCLUSIONS: Patients with EVD presented with evidence of dehydration associated with vomiting and severe diarrhea. Despite attempts at volume repletion, antimicrobial therapy, and limited laboratory services, the rate of death was 43%.
Asunto(s)
Deshidratación/etiología , Fiebre Hemorrágica Ebola/complicaciones , Fiebre Hemorrágica Ebola/mortalidad , Adulto , Factores de Edad , Antiinfecciosos/uso terapéutico , Diarrea/etiología , Ebolavirus , Epidemias , Femenino , Fiebre/etiología , Fluidoterapia , Guinea/epidemiología , Fiebre Hemorrágica Ebola/epidemiología , Humanos , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Riesgo , Tasa de Supervivencia , Taquicardia/etiología , Vómitos/etiologíaRESUMEN
The largest ever Ebola virus disease outbreak is ravaging West Africa. The constellation of little public health infrastructure, low levels of health literacy, limited acute care and infection prevention and control resources, densely populated areas, and a highly transmissible and lethal viral infection have led to thousands of confirmed, probable, or suspected cases thus far. Ebola virus disease is characterized by a febrile severe illness with profound gastrointestinal manifestations and is complicated by intravascular volume depletion, shock, profound electrolyte abnormalities, and organ dysfunction. Despite no proven Ebola virus-specific medical therapies, the potential effect of supportive care is great for a condition with high baseline mortality and one usually occurring in resource-constrained settings. With more personnel, basic monitoring, and supportive treatment, many of the sickest patients with Ebola virus disease do not need to die. Ebola virus disease represents an illness ready for a paradigm shift in care delivery and outcomes, and the profession of critical care medicine can and should be instrumental in helping this happen.
Asunto(s)
Cuidados Críticos/métodos , Fiebre Hemorrágica Ebola/terapia , Atención al Paciente/métodos , África Occidental/epidemiología , Enfermedad Crítica , Brotes de Enfermedades/estadística & datos numéricos , Fiebre Hemorrágica Ebola/epidemiología , Humanos , Cuidados Paliativos/métodosAsunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/prevención & control , Viaje , Adulto , Antimaláricos/efectos adversos , Atovacuona/efectos adversos , Atovacuona/uso terapéutico , Niño , Cloroquina/efectos adversos , Cloroquina/uso terapéutico , Doxiciclina/efectos adversos , Doxiciclina/uso terapéutico , Combinación de Medicamentos , Resistencia a Medicamentos , Quimioterapia Combinada/métodos , Humanos , Mefloquina/efectos adversos , Mefloquina/uso terapéutico , Primaquina/efectos adversos , Primaquina/uso terapéutico , Proguanil/efectos adversos , Proguanil/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
BACKGROUND: Malaria infects 10,000 to 30,000 international travellers each year. It can be prevented through anti-mosquito measures and drug prophylaxis. However, antimalaria drugs have adverse effects which are sometimes serious. OBJECTIVES: To compare the effects of currently used antimalaria drugs when given as prophylaxis to non-immune adult and child travellers who are travelling to regions with Plasmodium falciparum resistance to chloroquine. Specifically, to assess the efficacy, safety, and tolerability of atovaquone-proguanil, doxycycline, and mefloquine compared to each other, and also when compared to chloroquine-proguanil and to primaquine. SEARCH STRATEGY: In August 2009 we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2008, Issue 4), MEDLINE, EMBASE, LILACS, BIOSIS, mRCT, and reference lists. We handsearched conference proceedings and one specialist journal, and contacted researchers and drug companies. We searched PubMed for drug-related deaths. SELECTION CRITERIA: Randomized and quasi-randomized controlled trials of any antimalaria drug regimen currently used by non-immune international travellers. DATA COLLECTION AND ANALYSIS: We independently extracted data and assessed eligibility and risk of bias using a standardized data collection form. We resolved any disagreement through discussion. We combined dichotomous outcomes using risk ratio (RR) and continuous data using mean difference (MD), presenting both with 95% confidence intervals (CI). MAIN RESULTS: Eight trials (4240 participants) met the inclusion criteria. Evidence on comparative efficacy from head-to-head comparisons was limited. Atovaquone-proguanil compared to doxycycline had similar adverse events reported. Compared to mefloquine, atovaquone-proguanil users had fewer reports of any adverse effect (RR 0.72, 95% CI 0.6 to 0.85), gastrointestinal adverse effects (RR 0.54, 95% CI 0.42 to 0.7), neuropsychiatric adverse events (RR 0.86, 95% CI 0.75 to 0.99), and neuropsychiatric adverse effects (RR 0.49, 95% CI 0.38 to 0.63), besides a better total mood disturbance score (MD -7.20, 95% CI -10.79 to -3.61). Similarly, doxycycline users had fewer reported neuropsychiatric events than mefloquine users (RR 0.84, 95% CI 0.73 to 0.96). We also examined these three regimens against chloroquine-proguanil; this latter regimen had more reports of any adverse effect (RR 0.84, 95% CI 0.73 to 0.96) and of gastrointestinal adverse effects (RR 0.71, 95% CI 0.6 to 0.85). AUTHORS' CONCLUSIONS: Atovaquone-proguanil and doxycycline are the best tolerated regimens, and mefloquine is associated with adverse neuropsychiatric outcomes.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria Falciparum/prevención & control , Viaje , Adulto , Antimaláricos/efectos adversos , Atovacuona/efectos adversos , Atovacuona/uso terapéutico , Niño , Cloroquina/efectos adversos , Cloroquina/uso terapéutico , Doxiciclina/efectos adversos , Doxiciclina/uso terapéutico , Combinación de Medicamentos , Resistencia a Medicamentos , Quimioterapia Combinada/métodos , Humanos , Mefloquina/efectos adversos , Mefloquina/uso terapéutico , Primaquina/efectos adversos , Primaquina/uso terapéutico , Proguanil/efectos adversos , Proguanil/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
As the outbreak of Ebola virus disease (EVD) in West Africa continues, clinical preparedness is needed in countries at risk for EVD (e.g., United States) and more fully equipped and supported clinical teams in those countries with epidemic spread of EVD in Africa. Clinical staff must approach the patient with a very deliberate focus on providing effective care while assuring personal safety. To do this, both individual health care providers and health systems must improve EVD care. Although formal guidance toward these goals exists from the World Health Organization, Medecin Sans Frontières, the Centers for Disease Control and Prevention, and other groups, some of the most critical lessons come from personal experience. In this narrative, clinicians deployed by the World Health Organization into a wide range of clinical settings in West Africa distill key, practical considerations for working safely and effectively with patients with EVD.
Asunto(s)
Epidemias/prevención & control , Fiebre Hemorrágica Ebola/terapia , África Occidental/epidemiología , Atención a la Salud/organización & administración , Atención a la Salud/normas , Personal de Salud/psicología , Personal de Salud/normas , Fiebre Hemorrágica Ebola/epidemiología , Fiebre Hemorrágica Ebola/prevención & control , Humanos , Seguridad del Paciente , Ropa de ProtecciónRESUMEN
The Kenema Government Hospital Lassa Fever Ward in Sierra Leone, directed since 2005 by Dr. Sheikh Humarr Khan, is the only medical unit in the world devoted exclusively to patient care and research of a viral hemorrhagic fever. When Ebola virus disease unexpectedly appeared in West Africa in late 2013 and eventually spread to Kenema, Khan and his fellow healthcare workers remained at their posts, providing care to patients with this devastating illness. Khan and the chief nurse, Mbalu Fonnie, became infected and died at the end of July, a fate that they have sadly shared with more than ten other healthcare workers in Kenema and hundreds across the region. This article pays tribute to Sheik Humarr Khan, Mbalu Fonnie and all the healthcare workers who have acquired Ebola virus disease while fighting the epidemic in West Africa. Besides the emotional losses, the death of so many skilled and experienced healthcare workers will severely impair health care and research in affected regions, which can only be restored through dedicated, long-term programs.
Asunto(s)
Ebolavirus/fisiología , Fiebre Hemorrágica Ebola/epidemiología , Fiebre Hemorrágica Ebola/historia , África Occidental/epidemiología , Epidemias/historia , Personal de Salud/historia , Fiebre Hemorrágica Ebola/virología , Historia del Siglo XX , Historia del Siglo XXI , HumanosRESUMEN
This paper summarises the discussions and the recommendations formulated during a meeting in March 2007 on the challenges and strategies to increase the impact of maternal and childbirth health systematic reviews in the Americas. The discussions addressed three specific themes: (1) performing systematic reviews (2) updating existing reviews, and (3) diffusing and implementing evidence into practice. Practical recommendations were devised for each theme in small group discussions.